Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
6.34
+0.13 (2.09%)
At close: Aug 7, 2026, 4:00 PM EDT
6.34
0.00 (-0.01%)
After-hours: Aug 7, 2026, 7:57 PM EDT
Iovance Biotherapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 110.77 | 163.08 | 115.69 | 114.89 | 231.73 | 78.23 |
Short-Term Investments | 186.91 | 133.9 | 208.09 | 164.98 | 240.11 | 426.18 |
Cash & Short-Term Investments | 297.67 | 296.98 | 323.78 | 279.87 | 471.85 | 504.41 |
Cash Growth | -1.17% | -8.28% | 15.69% | -40.69% | -6.46% | -19.86% |
Accounts Receivable | 102.12 | 82.45 | 69.34 | 0.15 | - | - |
Inventory | 55.59 | 51.68 | 51.52 | 10.37 | - | - |
Other Current Assets | 8.87 | 11.58 | 12.38 | 17.46 | 7.27 | 3.55 |
Total Current Assets | 464.26 | 442.69 | 457.02 | 307.85 | 479.12 | 507.96 |
Net Property, Plant & Equipment | 174.94 | 177.01 | 164.28 | 176.55 | 178.25 | 169.92 |
Other Intangible Assets | 263.89 | 279.32 | 282.4 | 229.26 | - | - |
Long-Term Investments | - | - | - | - | - | 91.59 |
Other Long-Term Assets | 12.44 | 14.15 | 6.73 | 66.7 | 6.62 | 7.87 |
Total Assets | 915.53 | 913.17 | 910.43 | 780.35 | 663.98 | 777.33 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 26.21 | 22.16 | 27.51 | 33.12 | 26.6 | 27.38 |
Accrued Expenses | 77.96 | 111.16 | 81.94 | 69.41 | 52.3 | 56.77 |
Short-Term Debt | - | 1 | - | - | - | - |
Current Portion of Leases | 2.67 | 4.04 | 12.9 | 7.78 | 12.59 | 5.06 |
Total Current Liabilities | 106.85 | 138.36 | 122.34 | 110.31 | 91.49 | 89.2 |
Long-Term Debt | - | - | 1 | 1 | 1 | 1 |
Long-Term Leases | 43.33 | 44.4 | 44.37 | 67.09 | 71.86 | 65.47 |
Other Long-Term Liabilities | 29.31 | 31.83 | 32.32 | 17.35 | - | - |
Total Long-Term Liabilities | 72.64 | 76.23 | 77.68 | 85.43 | 72.86 | 66.47 |
Total Liabilities | 179.49 | 214.59 | 200.02 | 195.74 | 164.34 | 155.67 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Preferred Stock | - | 0 | 0 | 0 | 0 | 0 |
Common Stock | - | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-in Capital | 3,625 | 3,458 | 3,096 | 2,594 | 2,069 | 1,795 |
Accumulated Other Comprehensive Income | 13.08 | 16.44 | -1.05 | 2.53 | -0.9 | -0.6 |
Retained Earnings | - | - | - | -2,012 | -1,568 | -1,172 |
Shareholders' Equity | 3,638 | 3,474 | 3,095 | 584.61 | 499.64 | 621.66 |
Total Liabilities & Equity | 915.53 | 913.17 | 910.43 | 780.35 | 663.98 | 777.33 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 46 | 49.44 | 58.26 | 75.86 | 85.45 | 71.53 |
Net Cash (Debt) | 251.67 | 247.54 | 265.52 | 204.01 | 386.4 | 432.88 |
Net Cash Growth | 1.47% | -6.77% | 30.15% | -47.20% | -10.74% | -25.08% |
Net Cash Per Share | 0.61 | 0.69 | 0.92 | 0.87 | 2.43 | 2.82 |
Book Value | 3,638 | 3,474 | 3,095 | 584.61 | 499.64 | 621.66 |
Book Value Per Share | 8.87 | 9.72 | 10.68 | 2.49 | 3.14 | 4.05 |
Tangible Book Value | 3,374 | 3,195 | 2,813 | 355.36 | 499.64 | 621.66 |
Tangible Book Value Per Share | 8.23 | 8.94 | 9.70 | 1.51 | 3.14 | 4.05 |